Dual endothelin ET A and ET B receptor antagonists are approved therapy for pulmonary artery hypertension (PAH). We hypothesized that ET B receptor-mediated clearance of endothelin-1 at specific vascular sites may compromise this targeted therapy. Concentration-response curves (CRC) to endothelin-1 or the ET B agonist sarafotoxin S6c were constructed, with endothelin receptor antagonists, in various rat and mouse isolated arteries using wire myography or in rat isolated trachea. In Abbreviations: D 100 , artery (mesenteric or tail) internal diameter (µm) at an equivalent transmural pressure of 100 mm Hg; D 20 , artery (pulmonary) internal diameter (µm) at an equivalent transmural pressure of 20 mm Hg; Emax, maximum possible effect for the agonist; KPSS, isotonic potassium physiological salt solution (K + 124 mmol L À1 for arteries or K + 62 mmol L À1 for trachea); pEC50, negative log10 M concentration of agonist that evokes the half-maximal response; pKB, negative log10 M concentration of antagonist that shifted the agonist endothelin-1 EC50 twofold to the right; PSS, physiological salt solution.
| INTRODUCTION
In rats, 1 rabbits, 2 and nonhuman primates, 3 dual ET A and ET B receptor antagonists or ET B -selective endothelin-1 antagonists increased the immunoreactive endothelin-1 plasma level acutely by 3-to 10- fold. After chronic oral dosing in rats with A-182086, a dual ET A and ET B antagonist, the endothelin-1 plasma levels rose by more than 24-fold after 9 days. 4 Micro positron emission tomography using 18 F-labeled endothelin-1 in anesthetized rats confirmed that endothelin-1 rapidly binds to rat lung and is cleared from the circulation (t 0.5 0.43 minutes). 5 Pretreatment with the ET B -selective antagonist BQ788 decreased the endothelin-1 clearance by 85%.
While this intriguing mechanism of endothelin-1 clearance by ET B receptors was first determined in vivo, we asked, could this mecha- ) and further developed by Kenakin. 7 Indeed, we have previously reported that endothelin-1 concentration-contraction curves in rat small interlobar pulmonary arteries were surprisingly LEFT-shifted; ie, endothelin-1 contractions were "potentiated" in the presence of the dual ET A and ET B antagonist bosentan 10 lmol L À1 , 8 an observation that is consistent with blockade of a site of loss of endothelin-1.
Here, we report the pharmacodynamic interactions and analyses Group sizes were equal by design; however, variations due to predetermined criteria (described in the methodology) are explained in the figure legends. Animal tissues were randomized to treatment groups.
| Arteries
As previously described, 15 10 lmol L À1 bosentan were equilibrated before the concentrationresponse curve was constructed to endothelin-1. In each study, the artery was then exposed to a single cumulative concentration-con-
, depending on agonist, tissue, and treatment) to either sarafotoxin S6c or endothelin-1, added in half-log 10 M increments allowing time for the contraction to reach a plateau before raising the concentration.
| Endothelium removal
In rat small pulmonary artery, the normalization procedure was completed before testing the relaxation to acetylcholine 1 lmol 
| Trachea
The main trachea (10 mm long) was dissected free from the rat, cut into 2-to 3-mm-long ring segments, and mounted on wires in 15-mL organ baths (see figure 1 in Angus and Wright), 15 used for large diameter ring segments. In some trachea ring segments, the epithelial cell layer was removed by using a splinter of wood and gently rubbing the lumen for 1 minute. The rings were stretched to a passive F I G U R E 1 Average single exposure concentration-contraction curves to endothelin-1 in rat (A) mesenteric artery (n = 15) and (B) pulmonary artery (n = 15), pretreated with L-NAME 100 lmol L 
where n is a "power departure" equivalent to allowing the slope of a Schild plot to vary from unity (see Lew and Angus 22 ).
Having solved pK B , the relationship between the mean pEC 50 values of the actual data were plotted against the antagonist concentra-
). This graphical display was named the Clark plot by Stone and Angus 21 as it was similar to the plot developed by Statistical significance was taken when P < .05.
3 | RESULTS
| Rat mesenteric and pulmonary small arteries
In rat small mesenteric arteries (i.d. 352 AE 6 lm), single endothelin-1 concentration-response curves had a pEC 50 of 8.12 AE 0.02 and an
Emax of 108 AE 5% KPSS (n = 4; data not shown). In the presence of L-NAME (100 lmol L
À1
), the pEC 50 for endothelin-1 was 9.35 AE 0.13 (n = 6), significantly higher (17-fold more potent) than in the absence of L-NAME, and the Emax was 123 AE 9% KPSS (Figure 1A) . In rat small second-order pulmonary arteries (524 AE 20 lm The failure to obtain an estimate of the pK B for bosentan in rat small pulmonary artery, possibly due to the removal of the agonist endothelin-1, prompted the use of the nonendogenous ET B -selective ligand sarafotoxin S6c in the absence or presence of L-NAME. The control (0 lmol L À1 bosentan) curve was more potent (4.1-fold) in the presence of L-NAME (pEC 50 with L-NAME 9.31 AE 0.09, n = 6, and without L-NAME 8.70 AE 0.19, n = 5; Figure 2A values. n, number of arteries isolated from separate animals. Variations in n are due to violation of a predetermined criterion: arteries that contracted to KPSS with <1 mN force
Evidence that L-NAME or endothelial cell removal had abolished the relaxation to acetylcholine 1 lmol L À1 was shown by the result that before treatment with L-NAME or endothelial removal the relaxation to acetylcholine 1 lmol L À1 as a % of the precontractile tone was À54 AE 4% (n = 19) or À56 AE 2% (n = 18), respectively, and after treatment was À2 AE 2% or À1 AE 2%, respectively (data not shown).
| Other arteries
In the mouse, we examined 3 different arteries to determine if the responses to bosentan and endothelin-1 in the small pulmonary artery of the rat could be replicated. In the main pulmonary artery 
| Macitentan
In the rat small mesenteric artery, macitentan (0.3 and 1 lmol L
À1
) was a potent competitive endothelin-1 receptor antagonist (Figure 5A ). The Clark plot and analyses gave a pK B of 7.05 AE 0.10 (n = 15 points) and fitted the competitive model. The endothelin-1 concentration-contraction curves in the rat small pulmonary artery were completely unaffected by 1 and 10 lmol L À1 macitentan, as shown in Figure 5B .
| Ambrisentan
In the rat small mesenteric artery, ambrisentan (1 and 3 lmol L
À1
) was a potent competitive endothelin-1 receptor antagonist (Figure 5C ). The Clark plot and analyses gave a pK B of 6.60 AE 0.07 (n = 13 points) and fitted the competitive model. In contrast, endothelin-1 concentration-contraction curves in the rat small pulmonary artery were slightly left-shifted from control by ambrisentan 1 lmol L À1 before showing a small right-shift at 10 lmol L
( Figure 5D ). Figure 1C) . n, number of arteries isolated from separate animals. *P < .05, pEC 50 values compared with respective control (0 lmol L
) pEC 50 values. Variations in n are due to violation of predetermined criteria: pulmonary arteries that contracted to KPSS with <1 mN force; mesenteric arteries that contracted to KPSS with <3 mN force; or tail arteries that contracted to KPSS with <20 mN force ANGUS ET AL.
| 7 of 15

| Rat trachea
As was observed in rat small pulmonary artery, sarafotoxin S6c was significantly more potent than endothelin-1 in contracting the rat isolated trachea with the epithelium intact in the absence of any antagonist (pEC 50 values: sarafotoxin S6c 8.72 AE 0.22, n = 4; endothelin-1 6.82 AE 0.09, n = 7; Figure 6A ,B). In the absence of epithelium, the pEC 50 for sarafotoxin S6c was not changed (8.63 AE 0.13, n = 5) and similarly for endothelin-1 (6.61 AE 0.17, n = 4) ( Figure 6C,D) . The low potency of endothelin-1 in rat trachea prevented exploration of the full concentration-response curve, and therefore, we calculated pEC 50 values at responses of 50% KPSS maximum contraction. In contrast, the full sarafotoxin S6c concentration-response curves were obtained to allow pEC 50 values to be calculated from logistic curve analysis, often when the Emax was more than 100% KPSS. (n = 28 points; Figure 6E,F) . In epithelium-denuded trachea, with sarafotoxin S6c, the bosentan pK B was 6.06 AE 0.18 (n = 20 points), significantly higher than for endothelin-1 as agonist (pK B 5.02 AE 0.31, n = 17 points).
| Modeling
To model the interaction between endothelin-1 clearance and ET B and ET A receptor antagonism of the contraction response in small pulmonary arteries, we set the following criteria:
1. The ET B receptor-sensitive endothelin-1 clearance mechanism (C ETB ) can decrease the endothelin-1 concentration at the ET A or ET B receptor environment by a maximum of 10-fold (1 pEC 50 unit). In Figure 7A , we set the control pEC 50 for the sarafotoxin S6c concentration-response curve at 8.8 so that a twofold shift (log 0. ). Similarly, we set the control pEC 50 for endothelin-1 at 7.8. Assuming that the ET B (sarafotoxin S6c) assay was not compromised by clearance nor the endothelin-1 assay (like mesenteric artery or rat aorta), then the pEC 50 in the presence of the dual ET receptor antagonist (8.5-6.5
The theoretical dual ET
Àlog M) would rise as shown in Figure 7A and the Schild plot would show competitive antagonism (slope = 1) and pK B 8.5 ( Figure 7B) . If For the ET A receptor, the analysis is less certain as there is no selective ET A receptor agonist. 25 The main assay used to determine F I G U R E 7 (A) Hypothetical relationship between the pEC 50 values for endothelin-1 or sarafotoxin S6c concentration-contraction curves and the concentration of a theoretical dual ET A and ET B receptor antagonist with a pK B of 8.5 at both receptors. For simplicity, the control (0 antagonist) pEC 50 for sarafotoxin S6c ( ) was set 1 log unit higher (10-fold more potent) than for endothelin-1 ( ). In the presence of ET B receptors and the clearance (C) mechanism for endothelin-1, the maximum clearance was set at 10-fold (1 log unit) so that the pEC 50 in the presence of no antagonist (0) rises 1 log unit (• or ▲). As the ET B antagonism starts to block the endothelin-1 clearance, so the pEC 50 rises (•) but just as does the ET B and ET A antagonism so that the resultant shows the actual pEC 50 is not altered. (B) The Schild plot for endothelin-1 (or sarafotoxin S6c) as the agonist and the dual ET A and ET B antagonist with pK B of 8.5 is shown. Separate theoretical lines are shown for ET A ( ; eg, rat aorta) and ET B ( ; eg, trachea). In the presence of ET B -mediated clearance (C) that removes endothelin-1, as in pulmonary artery, the Schild plot points (▲) move parallel 1 log unit to decrease the potency of the dual antagonist by 10-fold (ie, the pK B of 8.5 becomes 7.5). The y axis is the agonist log(concentration ratio-1) and the x axis shows the concentration of dual ET A and ET B antagonist (Àlog M) the pK B (7.28) for bosentan at ET A receptors was the contraction to endothelin-1 of rat aortic rings, with endothelium removed. First to the role of nitric oxide, L-NAME made no significant difference to the pK B estimation for bosentan in rat small pulmonary artery ( Figure 2 ). L-NAME (100 lmol L À1 ) was effective in eliminat- Table 1 ). In the presence of ET B -mediated clearance, the plasma concentration of the dual antagonist must rise to 7.9 lmol L À1 to give a 10-fold antagonism at ET B receptors, with a fivefold antagonism at ET A receptors. The y axis is the agonist log(concentration ratio-1) and the x axis shows the concentration of dual ET A and ET B antagonist (Àlog M) ANGUS ET AL.
| 11 of 15 lowered to 7.2 (Àlog M) in the mesenteric artery, while in contrast, it was left-shifted and raised to a pEC 50 of 8.7 compared with control in the pulmonary artery ( Figure 1A,B) . We suggest that this anomalous result and inability to determine a pK B with bosentan in rat pulmonary artery is explained by the continuous removal of endothelin-1 by the ET B receptor-sensitive clearance mechanism found in this particular artery, but not in the rat mesenteric artery or aorta, nor human large pulmonary or radial artery. and BQ788 interaction ( Figure 3A ,E). But bosentan was close to being a competitive ET A antagonist in the pulmonary artery in the presence of L-NAME AND BQ788 to antagonize the clearance of endothelin-1 ( Figure 3C ,G). Similarly, in human pulmonary resistance arteries, the ET A receptor antagonist BMS182874 was ineffective against low concentrations of endothelin-1. 28 The finding that endothelium removal did not affect the EC 50 nor Emax to endothelin-1 or change the action of BQ788 in the rat small pulmonary artery compared to endothelium-intact tissues suggests that the arterial smooth muscle cells are the primary location of the proposed clearance mechanism (Figure 9 ).
In earlier work, Hay et al 29 reported that in rabbit pulmonary artery, sarafotoxin S6c gave a pK B of 7.7 for the mixed ET A and ET B receptor antagonist SB209670, but 6.7 when endothelin-1 was the agonist. In human small pulmonary arteries (150-200 lm i.d.) sarafotoxin S6c was more than 100-fold more potent than endothelin-1 and the authors concluded that both ET A and ET B receptor antagonists are required to antagonize endothelin-1. 28 We also found that the apparently weak antagonism of endothelin-1 by bosentan in rat pulmonary arteries is shared with ambrisentan and macitentan (Figure 5) . Indeed, these latter 2 endothelin-1 antagonists are more ET A than ET B receptor selective (Table 1) (Table 1) . Our theoretical modeling which reflects our in vitro experimental data (Figures 1 and 8A) suggests that to obtain (Table 1) , has been used in animals and
| Potential clinical implications
shows that effective ET A and ET B receptor antagonism was achieved after oral dosing. 24 Given that any antagonism of clearance will raise plasma endothelin-1 levels, there must be sufficient ET A receptor antagonism present to obviate vasoconstriction from this raised endothelin-1 concentration. Theoretically then, an ET A vs ET B selectivity of 10-fold would be sufficient, provided a high plasma concentration is achieved for ET B antagonism. From Table 1 , we predict that given clearance of endothelin-1 in important tissues such as pulmonary artery, the effective ET B antagonism is 10-fold weaker so that the ET A to ET B + clearance selectivity ratio increases by 10-fold. In effect, this suggests that the 3 antagonists in the clinic for pulmonary artery hypertension are principally ET A -selective agents. The 
